Cytochrome P450 2E1 gene polymorphisms/haplotypes and Parkinson's disease in a Swedish population

被引:23
作者
Shahabi, H. Niazi [1 ]
Westberg, L. [1 ]
Melke, J. [1 ]
Hakansson, A. [1 ]
Belin, A. Carmine [3 ]
Sydow, O. [4 ]
Olson, L. [3 ]
Holmberg, B. [2 ]
Nissbrandt, H. [1 ]
机构
[1] Univ Gothenburg, Sahlgrenska Acad, Dept Pharmacol, S-40530 Gothenburg, Sweden
[2] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Neurosci, Gothenburg, Sweden
[3] Karolinska Inst, Dept Neurosci, Stockholm, Sweden
[4] Karolinska Inst, Dept Neurosci, Stockholm, Sweden
基金
瑞典研究理事会;
关键词
Parkinson's disease; Cytochrome P450 2E1; Polymorphism; SNP; Haplotype; Taq-Man; MICROSOMAL EPOXIDE HYDROLASE; ALCOHOLIC LIVER-DISEASE; N-ACETYLTRANSFERASE; RAT SUBSTANTIA-NIGRA; CYP2E1; GENE; P450; ENZYMES; HEPATOCELLULAR-CARCINOMA; OXIDATIVE STRESS; LUNG-CANCER; HUMAN BRAIN;
D O I
10.1007/s00702-009-0221-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cytochrome P450 2E1 (CYP2E1), which inter alia is located in dopamine containing neurons in the substantia nigra, has been hypothesized to be of importance for the pathophysiology of Parkinson's disease (PD), either by its production of reactive oxygen species (ROS) or by its capability to detoxify putative neurotoxins. Numerous polymorphisms in the coding and non-coding regions of the gene for this enzyme have been reported. Different variants may account for inter-individual differences in the activity of the enzyme or production of ROS. In this study, the CYP2E1 gene was examined in a control population (n = 272) and a population with PD (n = 347), using a tag-single nucleotide polymorphism (tSNP) approach founded on HapMap Data. Six tSNPs were used in the analysis and haplotype block data were obtained. In case of significance, the SNP was further examined regarding early/late age of disease onset and presence of relatives with PD. We found an association between allele and genotype frequencies of the C/G polymorphism at intron 7 (rs2070676) of this gene and PD (P value of 0.026 and 0.027, respectively). Furthermore, analysis of the rs2070676 polymorphism in subgroups of patients with age of disease onset higher than 50 years and those not having a relative with PD also demonstrated a significant difference with controls. This was seen in both genotype (corresponding to P value = 0.039 and 0.032) and allele (P = 0.027 and 0.017 respectively) frequency. As a representative of many polymorphisms or in possible linkage disequilibrium with other functional variants, it is possible that rs2070676 could influence the regulation of the enzyme. In conclusion, our results display an association between the rs2070676 polymorphism and PD. Additional investigations are needed to elucidate the importance of this polymorphism for the activity of CYP2E1 and PD susceptibility.
引用
收藏
页码:567 / 573
页数:7
相关论文
共 52 条
[1]   What causes the build-up of ubiquitin-containing inclusions in Parkinson's disease? [J].
Andersen, JK .
MECHANISMS OF AGEING AND DEVELOPMENT, 2000, 118 (1-2) :15-22
[2]   Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease [J].
Bandmann, O ;
Vaughan, J ;
Holmans, P ;
Marsden, CD ;
Wood, NW .
LANCET, 1997, 350 (9085) :1136-1139
[3]  
Brockmoller J, 1996, CANCER RES, V56, P3915
[4]  
Brzezinski MR, 1999, J PHARMACOL EXP THER, V289, P1648
[5]   Human cytochrome P450 2E1 (CYP2E1): From genotype to phenotype [J].
Carriere, V ;
Berthou, F ;
Baird, S ;
Belloc, C ;
Beaune, P ;
deWaziers, I .
PHARMACOGENETICS, 1996, 6 (03) :203-211
[6]  
Daniel S E, 1993, J Neural Transm Suppl, V39, P165
[7]  
Danko IM, 2005, EXP ONCOL, V27, P248
[8]  
de Rijk MC, 2000, NEUROLOGY, V54, pS21
[9]   Prevalence of parkinsonism and Parkinson's disease in Europe: The EUROPARKINSON collaborative study [J].
deRijk, MC ;
Tzourio, C ;
Breteler, MMB ;
Dartigues, JF ;
Amaducci, L ;
LopezPousa, S ;
ManubensBertran, JM ;
Alperovitch, A ;
Rocca, WA .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1997, 62 (01) :10-15
[10]   Description of Parkinson's disease as a clinical syndrome [J].
Fahn, S .
PARKINSON'S DISEASE: THE LIFE CYCLE OF THE DOPAMINE NEURON, 2003, 991 :1-14